Stoke Therapeutics Förvaltning
Förvaltning kriterier kontrolleras 1/4
Vi har för närvarande inte tillräcklig information om VD:n.
Viktig information
Ian Smith
Verkställande direktör
US$27.0m
Total ersättning
| VD-lön i procent | 0.63% |
| Anställning som VD | 1.3yrs |
| Ägande av VD | n/a |
| Ledningens genomsnittliga anställningstid | 1.5yrs |
| Styrelsens genomsnittliga mandatperiod | 7.8yrs |
Senaste uppdateringar av ledningen
Recent updates
Uppdatering av berättelse • Jul 10
STOK: Phase 3 Dravet Data And NDA Timeline Will Drive Upside
Analysts have raised their fair value estimate for Stoke Therapeutics from $39.00 to $60.00, citing updated assumptions related to revenue growth, profitability, and a lower projected future P/E multiple. What’s in the News for Stoke Therapeutics Stoke Therapeutics has completed enrollment of 162 patients in the Phase 3 EMPEROR study of zorevunersen in Dravet syndrome.
Uppdatering av berättelse • Jun 26
None
Analysts have lifted their price target for Stoke Therapeutics from $34.25 to $45.10, citing updated assumptions around revenue growth, profitability, and a lower projected future P/E multiple as key drivers of the change. What’s in the News for Stoke Therapeutics No recent company specific news for Stoke Therapeutics was identified in the provided sources.Analysartikel • May 11
Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results
As you might know, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) just kicked off its latest quarterly results with some very...
Ny berättelse • May 11
Phase III Trial And Payer Risks Will Shape Dravet Treatment Prospects
Catalysts About Stoke Therapeutics Stoke Therapeutics is a biotechnology company focused on RNA-based medicines, including zorevunersen for Dravet syndrome. What are the underlying business or industry changes driving this perspective?Seeking Alpha • May 01
Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome
Summary I initiate Stoke Therapeutics with a Buy rating, driven by late-stage progress for zorevunersen in SCN1A Dravet Syndrome. STOK's phase 3 EMPEROR trial for zorevunersen targets mid-2027 data and a rolling NDA submission in the first half of 2027. Three-year open-label data show durable seizure reduction and functional improvement, supporting disease-modifying potential for zorevunersen. STOK's $390.9M cash position, Biogen partnership, and low burn rate provide runway into mid-2028, mitigating near-term financing risk. Read the full article on Seeking AlphaAnalysartikel • Jan 12
Newsflash: Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Have Been Trimming Their Revenue Forecasts
The analysts covering Stoke Therapeutics, Inc. ( NASDAQ:STOK ) delivered a dose of negativity to shareholders today, by...Analysartikel • Dec 05
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 36% But Its Business Still Trails The Industry
Despite an already strong run, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have been powering on, with a gain of...Analysartikel • Oct 09
Stoke Therapeutics, Inc. (NASDAQ:STOK) Held Back By Insufficient Growth Even After Shares Climb 39%
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have continued their recent momentum with a 39% gain in the last month...Analysartikel • Aug 25
Improved Revenues Required Before Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock's 49% Jump Looks Justified
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have continued their recent momentum with a 49% gain in the last month...Analysartikel • Aug 15
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Could Be 25% Above Their Intrinsic Value Estimate
NasdaqGS:STOK 1 Year Share Price vs Fair Value Explore Stoke Therapeutics's Fair Values from the Community and select...Analysartikel • May 20
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 28% But Its Business Still Trails The Industry
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders would be excited to see that the share price has had a great...Analysartikel • Apr 16
Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be
Market forces rained on the parade of Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders today, when the analysts...Analysartikel • Apr 05
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
To the annoyance of some shareholders, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares are down a considerable 27% in...Analysartikel • Feb 26
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Feb 16
Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer
Summary Stoke Therapeutics' RNA-based treatments for severe neurological and ophthalmic disorders, particularly zorevunersen for Dravet syndrome, show potential for long-term value beyond a single drug. Financials reveal high R&D spending and cash burn, but revenue growth from Acadia Pharmaceuticals collaboration suggests early monetization and potential non-dilutive funding. The Phase 3 EMPEROR study for zorevunersen is critical, with regulatory alignment and promising early data, but execution and long-term safety monitoring remain challenges. Stoke's broader pipeline, including treatments for SYNGAP1-related disorders, Rett syndrome, and Autosomal Dominant Optic Atrophy, could expand its market potential if RNA modulation proves broadly effective. Read the full article on Seeking AlphaAnalysartikel • Nov 08
Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) just released its third-quarter report and things are looking bullish. Results...Analysartikel • Nov 06
Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • Sep 07
Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
Summary STOK's zorevunersen shows strong efficacy in reducing seizures but has safety concerns, particularly elevated CSF protein levels, needing further monitoring. Dravet Syndrome market potential is significant, with 35,000 patients in key regions and existing treatments costing up to $96,000 annually. STOK has a solid cash runway for 7-8 quarters, with a Phase 3 trial expected to start soon, aiming for topline data by mid-2026. Despite recent stock gains, I may consider investing when Phase 3 trial enrollment is announced, given the promising genetic approach to Dravet Syndrome. Read the full article on Seeking AlphaAnalys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$170m |
| Dec 31 2025 | US$27m | US$171k | -US$7m |
| Sep 30 2025 | n/a | n/a | US$41m |
| Jun 30 2025 | n/a | n/a | US$52m |
| Mar 31 2025 | n/a | n/a | US$50m |
| Dec 31 2024 | US$248k | n/a | -US$89m |
| Sep 30 2024 | n/a | n/a | -US$105m |
| Jun 30 2024 | n/a | n/a | -US$104m |
| Mar 31 2024 | n/a | n/a | -US$109m |
| Dec 31 2023 | US$394k | n/a | -US$105m |
Ersättning vs marknad: Ian s total kompensation ($USD 27.03M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 5.18M ).
Ersättning vs inkomst: Ersättningen för Ian har ökat samtidigt som företaget är olönsamt.
VD OCH KONCERNCHEF
Ian Smith (60 yo)
1.3yrs
Anställning
US$27,031,655
Kompensation
Mr. Ian F. Smith, CPA, ACA, is CEO of Stoke Therapeutics, Inc. from October 6, 2025 and serves as its Director since September 19, 2023 and served as its Interim CEO from March 19, 2025 to October 6, 2025....
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO & Director | 1.3yrs | US$27.03m | inga uppgifter | |
| Co-Founder & Independent Director | no data | US$268.34k | 0.45% $ 8.3m | |
| Chief Financial Officer | 2.3yrs | US$1.83m | 0.016% $ 299.6k | |
| Advisor & Director | 1.3yrs | US$3.23m | 0.18% $ 3.3m | |
| Chief Patient Officer | 2.3yrs | US$2.27m | 0.017% $ 302.7k | |
| Co-Founder | no data | inga uppgifter | inga uppgifter | |
| Chief Scientific Officer | no data | inga uppgifter | inga uppgifter | |
| Director of Communications & Investor Relations | 1.5yrs | inga uppgifter | inga uppgifter | |
| Corporate Secretary & General Counsel | 5.4yrs | inga uppgifter | 0.029% $ 532.8k | |
| Vice President of Corporate Communications | less than a year | inga uppgifter | inga uppgifter | |
| Chief People Officer | 1.5yrs | inga uppgifter | inga uppgifter | |
| Chief Medical Officer | 8.8yrs | US$2.47m | 0.044% $ 813.0k |
1.5yrs
Genomsnittlig anställningstid
57yo
Genomsnittlig ålder
Erfaren ledning: STOK s ledningsgrupp anses inte vara erfaren ( 1.5 års genomsnittlig anställningstid), vilket föreslår ett nytt team.
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| CEO & Director | 2.8yrs | US$27.03m | inga uppgifter | |
| Co-Founder & Independent Director | 12.1yrs | US$268.34k | 0.45% $ 8.3m | |
| Advisor & Director | 8.8yrs | US$3.23m | 0.18% $ 3.3m | |
| Independent Director | 11yrs | US$270.84k | 3.01% $ 55.2m | |
| Independent Director | 10.8yrs | US$281.25k | 0.036% $ 654.5k | |
| Independent Director | 6.1yrs | US$283.34k | 0% $ 0 | |
| Independent Director | 7.1yrs | US$283.34k | 0% $ 0 | |
| Chairman of the Board | 7.8yrs | US$778.78k | 0.050% $ 923.3k | |
| Independent Director | less than a year | inga uppgifter | inga uppgifter |
7.8yrs
Genomsnittlig anställningstid
66yo
Genomsnittlig ålder
Erfaren styrelse: STOK s styrelse anses vara erfaren ( 7.8 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/14 23:28 |
| Aktiekurs vid dagens slut | 2026/07/14 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Stoke Therapeutics, Inc. bevakas av 22 analytiker. 12 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| Thomas Shrader | BTIG |
| Michelle Gilson | Canaccord Genuity |